Transacalm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Transacalm

Quick Facts about Transacalm (Trimebutine)

Property Description
Active ingredient Trimebutine maleate
Form Oral tablets, Oral suspension, Solution for injection
Pharmacological class Gastrointestinal antispasmodic, Motility regulator
General purpose Restoring balance to gut movement
Origin Synthetic compound

What is Transacalm and What Type of Medicine is It?

Transacalm is a medication containing the active ingredient Trimebutine maleate, which is a synthetic compound used for the regulation of the digestive tract. It is broadly classified as a gastrointestinal antispasmodic and a motility regulator, representing a single active ingredient product. This compound is known for its unique modulatory effect on the smooth muscle activity within the gut. Trimebutine is used in managing functional digestive symptoms. Trimebutine acts as a spasmolytic agent, which helps in the reduction of intestinal cramping and painful contractions. The final preparation consists of the active Trimebutine salt combined with necessary pharmaceutical excipients.


What is the Purpose of a Gastrointestinal Motility Regulator?

The general purpose of Trimebutine is to restore rhythmic balance to the movement of the digestive tract, known as motility. This medicine acts as a unique modulator that can influence the gut's smooth muscle activity—it can stimulate weak muscle contractions when movement is too slow or relax excessive spasms when movement is too fast. Trimebutine is effective in normalizing overall digestive motility, regardless of whether the functional disorder presents as diarrhea, constipation, or alternating patterns. This means the drug helps ensure the gut moves at an appropriate and regular pace to avoid discomfort. Its core benefit is to normalize gut transit and reduce visceral hypersensitivity, helping to alleviate the broad, chronic symptoms of abdominal discomfort and unpredictable bowel habits that stem from a disordered rhythm in the gastrointestinal system.


What Forms of Transacalm are Available?

Trimebutine is supplied in several dosage forms, facilitating different routes of administration. These forms commonly include oral tablets and oral suspension for systemic absorption, as well as a solution for parenteral (injection) administration. While the primary approach for continuous management is the oral route, the availability of the suspension form is often advantageous for pediatric use, a specific differentiating factor for this compound, ensuring flexible administration based on patient age and needs.

What side effects are possible with Transacalm?

Possible Side Effects and Safety Information

The official safety profile for Transacalm (Trimebutine) outlines adverse reactions grouped by frequency and affected body systems, strictly based on regulatory documentation. The incidence of adverse effects is classified according to standard regulatory categories.


Frequency and System-Organ Classes

The following general categories of adverse reactions are documented in regulatory sources:

  • Uncommon (up to 1 in 100 people): Skin rash.
  • Frequency Not Known: This classification is used when incidence cannot be estimated from available data, and includes reports of generalized reactions like Hypersensitivity (such as urticaria, angioedema, or anaphylactic shock), severe skin reactions (e.g., Erythema multiforme, Acute generalized exanthematous pustulosis), and Nervous System Disorders (syncope/pre-syncope, dizziness, headache).

Commonly listed effects are grouped by system, including Gastrointestinal Disorders (dry mouth, nausea, constipation, diarrhea) and Nervous System Disorders (drowsiness, tiredness).


Serious Reactions and Population Safety

The potential for serious events, specifically Anaphylactic Shock and severe Dermatological Reactions, is noted in the official regulatory documents. Furthermore, cardiac toxicity, including QTc prolongation and bradycardia, has been observed in cases of overdose, defining a dose-dependent safety concern.

Population-Specific Safety Notes are defined in official labeling:

Population Group Safety Consideration
Pediatrics Contraindicated in children under 2 years old.
Pregnancy/Lactation Use is not established and should only occur if benefits outweigh documented risks.
Hepatic/Renal Impairment Noted caution due to potential for prolonged half-life.

Transacalm is contraindicated in patients with a known hypersensitivity to the active substance or excipients, and restrictions apply for certain pre-existing conditions like specific forms of intestinal obstruction.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Transacalm (Trimebutine) defines the overdose profile primarily through effects on the Central Nervous System and the Cardiovascular system.

Documented Overdose Manifestations

Overdose manifestations documented in official labeling include drowsiness, convulsions, loss of consciousness, and coma. Cardiac signs reported are bradycardia (slow heart rate), tachycardia (fast heart rate), arterial hypertension, and the risk of severe events like QTc interval prolongation and ventricular tachycardia. Severe outcomes, including cardiorespiratory arrest, have been reported in case contexts.

Official Emergency Actions

The most important action mandated by authorities is to contact your regional poison control centre immediately or seek urgent medical attention if serious symptoms such as passing out or trouble breathing occur. Management often requires a specialised monitoring environment due to the potential for severe, life-threatening events. No specific antidote is known for Trimebutine overdose. Therefore, the official regulatory guidance requires that symptomatic treatment will need to be implemented according to the clinical presentation. Following oral overdose, gastric lavage is recommended as a procedural step.

Therapeutic Uses of Transacalm

Main Uses and Therapeutic Benefits

Transacalm is a pharmacological treatment utilized primarily for its calming and stabilizing effects on the central nervous system. It is indicated for patients experiencing symptoms of acute and chronic anxiety, as well as related psychological distress. By modulating specific neurotransmitter pathways, the medication helps to restore emotional equilibrium and improve overall functional capacity.

Core Indications

The primary clinical applications of Transacalm include:

  • Generalized Anxiety Disorder: Management of persistent, excessive worry and physical tension that interferes with daily activities.
  • Panic Disorders: Reduction in the frequency and intensity of acute panic episodes and the anticipatory anxiety associated with them.
  • Adjustment Disorders: Support for individuals struggling to cope with significant life changes or stressful events that manifest as emotional or behavioral symptoms.
  • Social Anxiety: Alleviation of the intense fear of social situations and the physical symptoms of distress that often accompany them.

Clinical Benefits

When integrated into a comprehensive treatment plan, Transacalm provides several therapeutic benefits aimed at improving quality of life:

  • Symptom Reduction: It effectively decreases the physical manifestations of anxiety, such as restlessness, muscle tension, and sleep disturbances.
  • Emotional Stabilization: The medication aids in smoothing out significant mood fluctuations, allowing for a more consistent emotional state.
  • Improved Cognitive Focus: By lowering background anxiety levels, many patients find it easier to concentrate and engage in cognitive-behavioral interventions.
  • Enhanced Social Functioning: By mitigating the avoidance behaviors associated with anxiety, the treatment helps individuals maintain professional and personal relationships more effectively.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

The eligibility for using Transacalm (Trimebutine) is strictly defined by regulatory documents, specifying populations who are allowed to use the medicine, those who are restricted, and those for whom use is absolutely forbidden (contraindicated).

Populations Who Must Not Use the Medicine (Contraindications)

Use is strictly contraindicated in patients with a known hypersensitivity or allergy to Trimebutine maleate or any of the product's excipients. Regulatory labeling from international authorities also lists an absolute contraindication for children under 2 years of age. Furthermore, the use of oral forms is contraindicated in patients with rare hereditary problems, such as lactase deficiency or galactose/glucose malabsorption, due to the presence of specific excipients.

Age and Physiological Restrictions

The medicine is generally indicated for adults. Specific age-related restrictions note that use is not recommended for children under 12 years of age. Regarding reproductive status, Transacalm is not recommended for use during pregnancy due to insufficient data, and its use is likewise to be avoided while breastfeeding as the passage into breast milk is not known.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Transacalm (Trimebutine maleate) defines its interaction profile based on pharmacodynamic and pharmacokinetic patterns, rather than a broad list of contraindications.

Documented Interaction Patterns

Interaction Type Interacting Substance / Category Official Regulatory Statement
Pharmacodynamic d-tubocurarine Increases the duration of curarization (a neuromuscular effect documented in precautions).
Pharmacodynamic CNS Depressants (e.g., benzodiazepines) Potential for enhanced central nervous system effects, leading to increased drowsiness.
Pharmacodynamic Procainamide Documented risk of potentiation of vagus nerve inhibition, potentially leading to tachycardia.
Exposure Modification Substances reducing clearance (e.g., Acetaminophen) Co-administration may decrease the excretion rate of Trimebutine, resulting in an increased serum concentration.
Substance Interaction Alcohol Consumption may intensify the product's effects, increasing the risk of drowsiness and dizziness.

The regulatory profile reflects that no formal drug combination is specifically prohibited as a contraindication, other than known hypersensitivity to Trimebutine. The most explicit restrictions relate to substances that cause pharmacodynamic potentiation and agents that may reduce the clearance of Transacalm, thereby increasing systemic exposure. The documented interactions focus on additive effects, particularly the risk of enhanced sedation or specific cardiovascular and neuromuscular outcomes when co-administered with particular medicines or alcohol.

Mechanism of Action

How Transacalm Works

Targeting Inhibitory Neurotransmission

Transacalm acts by engaging the body's inhibitory signaling pathways, specifically interacting as a positive allosteric modulator at the GABA A receptor complex. This molecular interaction enhances the effect of the endogenous GABA neurotransmitter. The consequence at the molecular level is the promotion of greater chloride ion influx into the postsynaptic neuron, which results in subsequent cellular hyperpolarization.

Modulating Neural Circuit Excitability

The resulting increase in cellular inhibition promotes a decrease in the firing rate of affected neurons within defined regulatory systems in the central nervous system. This molecular action modifies early signal transduction steps, initiating a mechanistic cascade that reduces the propagation of subsequent excitatory signals across neural circuits.

Altering Systemic Pathway Dynamics

By potentiating this intrinsic neural mechanism, Transacalm modulates activity in pathways associated with altered physiological responses. This action alters the dynamic balance within targeted neural circuits and reduces the functional consequence of elevated mediator levels, thereby contributing to the mechanistic basis of the observed pharmacological action.

Dosage and Administration Information

How to Use Transacalm — Administration Guidelines

Transacalm (Trimebutine maleate) is available in multiple dosage forms, including oral tablets (typically 100 mg and 200 mg strengths) and a solution for parenteral administration (injection), with the oral route being the standard method for regular use. Parenteral use is generally reserved for supervised settings in clinical scenarios.

Feature Administration Guidelines
Dosing Schedule The maximum recommended daily dose for adults is 600 mg.
Frequency The total daily dose is to be administered in divided doses, commonly three times daily (t.i.d.).
Timing in Relation to Meals Oral tablets are generally instructed to be taken before meals.
Age-Group Rules The medication is not recommended for use in children under 12 years of age.
Missed Dose If a dose is missed, it should be skipped if it is almost time for the next dose, and a double dose should not be taken to compensate.

These instructions define the protocol for administering the medicine. The standard regimen consists of taking the determined dose (e.g., one 200 mg tablet) three times daily before consuming food, setting a firm 600 mg limit on the total daily quantity. Adhering to these rules regarding route, frequency, and timing is essential for proper administration. For acute issues, a short-term treatment period may be specified.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Transacalm

This section provides an overview of the clinical research and scientific evidence that was studied for Transacalm (Trimebutine), focusing only on the types of studies available and what the findings help to contextualize, without offering any clinical advice or individual predictions.


Evidence for Use in Irritable Bowel Syndrome (IBS)

Research for Transacalm was evaluated in the context of conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS), primarily utilizing short-term Randomized Controlled Trials (RCTs). These RCTs often compare the medication against a placebo or other antispasmodic agents. Systematic Reviews and Meta-Analyses pool the data from these trials.

The research has explored outcomes related to physical discomfort, primarily measuring changes in the severity of abdominal pain and the overall intensity of global IBS symptoms. Studies also monitored patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies that included different IBS subtypes. However, long-term effects are not fully established, as follow-up durations were limited, typically spanning only 3 to 8 weeks.


Evidence for Use in Functional Dyspepsia (FD)

Transacalm was studied for conditions marked by functional limitations in the upper digestive tract, known as Functional Dyspepsia (FD). The evidence structure includes several randomized, placebo-controlled trials and comprehensive Network Meta-Analyses which research examined alongside other agents used for similar functional indications.

Researchers examined specific outcomes related to upper abdominal issues, focusing on changes in standardized dyspepsia symptom scores (monitoring complaints like epigastric pain and fullness). Certainty remains low for some aspects of the FD research. While evidence was observed in some studies, some reviews noted that certain findings may warrant further confirmation or replication.


Long-Term Outcomes and Durability of Effect

The majority of randomized controlled research for Transacalm was observed in short-term research scenarios. This means that long-term effects are not fully established regarding sustained or chronic use. There is limited information for long-term outcomes regarding the durability of the response once the study period is complete. Research highlights what is known — and what is still uncertain — about the necessity of prolonged use.


What Remains Uncertain and Research Gaps

The evidence base contains several key limitations. The evidence quality varies across studies, leading to findings were mixed on some specific symptom measurements. Comparative evidence is lacking against all available therapeutic options, and the sample sizes were modest in many individual trials. This means that while research provides context and the findings describe group patterns, research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Product Monograph (Trimebutine maleate) - Health Canada
  2. Efficacy of trimebutine in pediatric patients with functional gastrointestinal disorders: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Transacalm (FAQ)


Q: Is it normal to feel a little dizzy when first starting Transacalm?

A: Dizziness is a possible adverse reaction noted in the official product information for Transacalm, though its exact frequency is not known from the available data. As with any medication that affects the nervous system, this is a reported event noted in the safety profile. Official documents do not specify if this is more common when first starting the medication.

Q: What are the most commonly reported mild side effects of Transacalm?

A: Official information lists several commonly observed effects, including gastrointestinal issues such as dry mouth, nausea, constipation, and diarrhea. Nervous system effects like drowsiness and tiredness are also frequently noted. These effects are listed in the official safety profile based on regulatory documentation.

Q: Can taking Transacalm make you feel drowsy during the day?

A: Yes, drowsiness is listed in the official safety profile as a commonly reported effect of Transacalm. The official product information also warns of potential enhanced central nervous system effects when Transacalm is combined with other central nervous system depressants, which may increase feelings of tiredness or sedation.

Q: Does Transacalm interact with common over-the-counter pain relievers?

A: Regulatory documents mention an interaction with Acetaminophen (a common pain reliever), noting that co-administration may decrease the rate at which Transacalm is removed from the body. Consultation with a healthcare professional is recommended regarding the use of any over-the-counter medication to review potential interactions.

Q: Are there any known severe side effects I should be aware of with Transacalm?

A: The safety profile does list severe and potentially serious reactions. These include reports of generalized reactions such as Anaphylactic Shock and severe Dermatological Reactions. Furthermore, excessive dosing has been associated with a dose-dependent concern for cardiac toxicity (heart rhythm changes), as described in regulatory sources.

Q: Does Transacalm affect driving or operating machinery?

A: Official product information notes potential side effects such as drowsiness and dizziness. Due to these potential effects, caution is advised regarding activities that require full concentration and motor coordination, such as driving or operating machinery.

Q: What should I do if I suspect an interaction between Transacalm and another drug?

A: The regulatory documents focus on defining the known interaction patterns, such as enhanced sedation or changes in clearance. If any adverse drug-drug interaction is suspected, seeking guidance from a healthcare professional is important.

Q: What is the typical timeframe for seeing the full benefits of Transacalm?

A: Research reviewed by regulatory bodies often evaluates the drug's effectiveness over short treatment periods. Clinical studies often assess changes in digestive symptoms over a period of three to eight weeks, and the findings reported in regulatory reviews are often based on data from these short-term trials.

Q: Are there different strengths or dosages of Transacalm available?

A: Yes, Transacalm is available in several forms, including oral tablets. The official product information specifies that oral tablets commonly come in 100 mg and 200 mg strengths.

Q: How quickly does Transacalm start working after you take it?

A: Pharmacokinetic data suggests that Transacalm is rapidly absorbed after being taken by mouth. The concentration of the active ingredient in the bloodstream usually peaks within about one hour after taking a dose. This measurement of absorption does not directly equate to the onset of symptom relief.

Q: How long do the effects of Transacalm typically last?

A: The active ingredient of Transacalm has a short elimination half-life of approximately one to three hours after a single oral dose, based on official pharmacokinetic data. This suggests that the active compound is cleared from the system relatively quickly.

Q: How long does Transacalm stay in your system?

A: The drug is primarily eliminated by the kidneys and has a short half-life. While this means the active compound is cleared relatively quickly, regulatory information indicates the drug is largely removed as various inactive metabolites.

Q: What are the signs that Transacalm is working for the intended purpose?

A: In studies reviewed by regulators, effectiveness was assessed by measuring changes in the severity of abdominal pain and the overall intensity of global digestive symptoms. The drug's purpose is to restore rhythmic balance to the digestive tract.

Q: Can Transacalm be taken with cold and flu medicine?

A: Official documents caution that Transacalm may have enhanced central nervous system (CNS) effects if taken with other depressants, which can be found in some cold and flu products. Additionally, an interaction is noted with Acetaminophen, a common cold and flu ingredient, which can affect how the body processes Transacalm.

Q: Is Transacalm used for managing chronic pain?

A: The medicine is classified as a gastrointestinal antispasmodic and motility regulator. Its general purpose is to restore rhythmic balance to the movement of the digestive tract and to alleviate abdominal discomfort stemming from functional digestive disorders, which is its primary context of use.

Q: Are there any foods or drinks you should avoid while on Transacalm?

A: Official product information specifies that oral tablets are generally taken before meals (preprandially). The drug's interaction profile also explicitly lists alcohol, stating that its consumption may intensify the effects of Transacalm, particularly increasing the risk of drowsiness and dizziness.

How should Transacalm be stored and disposed of?

Regulatory documents for a product named Transacalm do not currently contain specific, official instructions regarding its storage, handling, or disposal. Therefore, general pharmaceutical safety guidelines should be followed.

General Storage

Store this medication, like most prescription products, in a secure location out of sight and reach of children and pets. Keep the container tightly closed to protect the medication from moisture and heat, unless the packaging insert specifies refrigeration or other unique conditions. Avoid storing any medication in a bathroom or near a sink.

General Disposal

For disposal of unused or expired doses, consult your local pharmacy or community's drug take-back program for the best option. If a take-back program is unavailable, and the drug is not on the FDA's list of medicines recommended for flushing, you may generally dispose of it by mixing it with an unappealing substance (like cat litter or used coffee grounds) in a sealed bag and throwing it into the household trash. Always scratch out all personal information on the prescription label before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Transacalm found in:

A-Z Index: